Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 138

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 138
---
any Person which is a party to any Contract required to be listed pursuant to Section ‎3.17.0other than, in the case of clauses (b)and (c)above, as a Person owning beneficially less than 1% of the equity of such entity; or (iii)has outstanding any Indebtedness owed to SKNY, or is the obligee or beneficiary of any liability of SKNY, in each case, except for employment-related compensation or liabilities therefor received or payable in the ordinary course of business or any rights or obligations such Related Party may have in its capacity as a holder of SKNY Common Stock.

3.20 Brokers. Except as set forth on Section ‎3.20of the SKNY Disclosure Schedule, no broker, finder, or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement or any of the other Transaction Agreements based upon arrangements made by or on behalf of SKNY.

3.21 Employee Benefits. SKNY does not have and has never had any employees.

3.22 Indebtedness. Section 3.22 of the SKNY Disclosure Schedule sets forth all outstanding Indebtedness of SKNY as of March 31, 2025, including the amount outstanding with respect thereto.

3.23 Real Property. SKNY does not own or lease, and has never owned or leased, any real property.

3.24 Anti-Takeover Statutes. SKNY is not bound by or has in effect any “poison pill” or similar shareholder rights plan.

3.25 No Other Representations. SKNY acknowledges that none of the Company, Merger Sub or any of their Representatives or any other Person makes, and SKNY acknowledges that it has not relied upon or otherwise been induced by, any express or implied representation or warranty with respect to the Company or Merger Sub or with respect to any other information provided or made available to SKNY or its Representatives in connection with this Agreement and the transactions contemplated hereunder, including any information, documents, projections, forecasts or other material made available to SKNY in certain “data rooms” or management presentations in connection with this Agreement or the transactions contemplated hereunder or the accuracy or completeness of any of the foregoing, except, in each case for the representations and warranties contained in ‎ Article IVof this Agreement and in any certificate delivered by Company or Merger Sub under this Agreement.

| 14 |

<div align='center'>Article IV